senktide has been researched along with zd 6021 in 1 studies
| Studies (senktide) | Trials (senktide) | Recent Studies (post-2010) (senktide) | Studies (zd 6021) | Trials (zd 6021) | Recent Studies (post-2010) (zd 6021) |
|---|---|---|---|---|---|
| 292 | 1 | 50 | 5 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbott, BM; Aharony, D; Albert, JS; Barthlow, HG; Bernstein, PR; Bialecki, RA; Brown, F; Caccese, R; Ghanekar, S; Lengel, D; McCarthy, M; Ohnmacht, C; Rumsey, WL; Russell, K; Shenvi, A; Undem, B; Wenrich, B | 1 |
1 other study(ies) available for senktide and zd 6021
| Article | Year |
|---|---|
Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Topics: Administration, Oral; Animals; Bronchoconstriction; Cricetinae; Guinea Pigs; Humans; Ileum; Male; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Piperidines; Pulmonary Artery; Rabbits; Receptors, Neurokinin-1; Receptors, Neurokinin-2; Receptors, Neurokinin-3; Receptors, Tachykinin; Substance P; Sulfoxides | 2001 |